Article Sidebar

Submitted
6 August 2020
Accepted
6 August 2020
Published
30 June 2020
Download
PDF
Statistic
Read Counter : 865 Download : 677

Main Article Content

Abstract

This study aimed to analyze the effect of glucose induction on the clinical isolate biofilm density of Acinetobacter baumannii. Thirteen clinical isolates of A. baumannii non biofilm forming were collected from non-DM patients who were treated at the ICU of Dr. Soetomo Hospital, Surabaya, was treated with the addition of 0.08% glucose, 0.15% glucose, 0.2% glucose, and 0.4% glucose in TSB growth media, followed by biofilm density examination with Tissue Culture Plate Method (TCPM) using 96 wells flatbottomed polyesterene tissue culture plate and read by autoreader ELISA with a wavelength of 630 nm (OD630). Biofilm density obtained was analyzed using ANOVA statistical analysis. The results of OD630 showed that the biofilm density increased significantly at the addition of 0.2% and 0.4% glucose. There was a significant increase in biofilm density at the addition of 0.2% and 0.4% glucose so that the management of blood sugar levels in ICU patients was needed before and when medical devices were installed.

Keywords

Biofilm density glucose A. baumannii

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Lindarto, W. W., Wasito, E. B., & Debora, K. (2020). Effect of Glucose Induction on Biofilm Density in Clinical Isolate Acinetobacter baumannii Patients in Intensive Care Unit of Dr. Soetomo Hospital, Surabaya. Folia Medica Indonesiana, 56(2), 118–126. https://doi.org/10.20473/fmi.v56i2.21230
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Amyes SGB, Young HK (1996). Mechanisms of antibiotic resistance in Acinetobacter spp. - genetics of resistance. Acinetobacter: Microbiology, Epidemiology, Infection, Management. New York, CRC Press, p 185-223
  2. Anandhalakshmi S, Shasshikala N, Noyal MJ, Reba K (2017). Profile of multidrug resistant Acinetobacter baumannii infections among hospitalized patients. Journal of Medical Science and Clinical Research. V5i6, 23111-23115
  3. Arisma BJN, Yunus M, Fanani E (2017). Gambaran pengetahuan masyarakat tentang resiko penyakit diabetes mellitus di kecamatan Pakisaji kabupaten Malang. Preventia. Available at http://www.journal. um.ac.id/index.php/preventia/article/view/10010/4753
  4. Badave GK, Dhananjay K (2015). Biofilm producing multidrug resistant Acinetobacter baumannii: An emerging challenge. Journal of Clinical and Diagnostic Research 9, DC08-DC10
  5. Bergogne-Bérézin E, Towner KJ (1996). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9, 148-165
  6. Beveridge TJ (1999). Structures of Gram-negative cell walls and their derived membrane vesicles. J. Bacteriol. 181, 4725-4733
  7. Blanco N, Harris AD, Rock C, Johnson K, Pineles L, et al (2018). Risk factors and outcomes associated with multidrug-resistant Acinetobacter baumannii upon ICU admission. AAC. DOI: 10.1128/AAC.01631-17
  8. Borer A, Gilad J, Smolyakov R, et al (2005). Cell phones and Acinetobacter transmission. Emerg Infect Dis 11, 1160-1161
  9. Brégeon D, Colot V, Radman M, Taddei F (2001). Translational misreading: a tRNA modification counteracts a +2 ribosomal frameshift. Genes Dev. 15, 2295-2306
  10. Buisson Y, Nhieu, GT, Ginot L, Bouvet P, Shill H, Driot L, Meyran M (1990). Nosocomial outbreaks due to amikacin-resistant tobramycin sensitive Acinetobacter species: correlation with amikacin usage. J Hosp Infect 15, 83-93
  11. Cabral MP, Soares NC, Aranda J, et al (2011). Proteomic and functional analyses reveal a unique lifestyle for Acinetobacter baumannii bioflms and a key role for histidine metabolism. J. Proteome Res. 10, 3399-3417
  12. Costerton JW, Stewart PS, Greenberg EP (1999). Bacterial biofilms: a common cause of persistent infections. Science 284: 1318-1322
  13. Costerton W, et al (2003). The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 112, 1466-77
  14. Cox RA (2004). Quantitative relationships for specifc growth rates and macromolecular compositions of Mycobacterium tuberculosis, Streptomyces coelicolor A3 (2) and Escherichia coli B/r: an integrative theoretical approach. Microbiology 150, 1413-1426
  15. Dijkshoorn L, Nemec A, Seifert H (2007). An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5, 939-951
  16. Donlan RM, Costerton JW (2002). Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15, 167-193
  17. Donlan RM (2001). Biofilm formation: A clinically relevant microbiological process. Clinical Infectious Diseases 33, 1387-92
  18. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C (1996). Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 23, 538-542
  19. Fani R, Brilli M, Fondi M, Lió P (2007). The role of gene fusions in the evolution of metabolic pathways: the histidine biosynthesis case. BMC Evol. Biol. 7, S4
  20. Gaddy JA, Tomaras AP, Actis LA (2009). The Acinetobacter baumannii (19606) OmpA protein plays a role in biofilm formation on abiotic surfaces and the interaction of this pathogen with eukaryotic cells. Infect Immun 77, 3150-3160
  21. Garnacho-Montero J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J (2003). Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 31, 2478-2482
  22. Giannouli M, Antunes LC, Marchetti V, Triassi M, Visca P, Zarrilli R (2013). Virulence-related traits of epidemic Acinetobacter baumannii strains belonging to the international clonal lineages I-III and to the emerging genotypes ST25 and ST78. BMC Infect Dis 13, 282
  23. Haryani S, Defrin, Yenita (2016). Prevalensi kanker serviks berdasarkan paritas di RSUP dr. M. Djamil Padang periode Januari 2011-Desember 2012. Jurnal Kesehatan Andalas 5, 647-652
  24. Hsu LY, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA (2017). Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clinical Microbiology Revi. 30, 1-22
  25. Joly-Guillou ML, Brun-Buisson C (1996). Epidemiology of Acinetobacter spp.: surveillance and management of outbreaks. Acinetobacter-Microbiology, Epidemiology, Infection, Management. New York, CRC Press, p 71-100
  26. Joly-Guillou ML, Decre D, Herrman JL, Bourdelier E, Bergogne-Berezin E (1995). Bactericidal in-vitro activity of ß-lactams and ß-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. J Antimicrob Chemother 36, 619-629
  27. Kapatral V, Campbell JW, Minnich SA, Thomson NR, Matsumura P, Pr€uss, BM (2004). Gene arrays analysis of Yersinia enterocolitica FIhD and FIhC: regulation of enzymes affecting synthesis and degradation of carbamoylphosphate. Microbiology 150, 2289-2300
  28. Khosama Y (2015). Faktor resiko kanker kolorektal. CDK 234 42, 829-832
  29. Kitagawa K, Tateishi A, Nakano F, Matumoto I, Morohoshi I, Tanino T, Osui T (1986). Generation of energy coupled with membrane-bound glucose dehydrogenase in Acinetobacter calcoaceticus. Agric. Bioi. Chem. 50
  30. Lambert T, Gerbaud G, Bouvet P, Vieu Jf, Courvalin P (1990). Dissemination of amikacin resistance gene aphA6 in Acinetobacter spp. Antimicrob Agents Chemother 34, 1244-1248
  31. Lee JC, Koerten H, van den Broek P, et al (2006). Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol 157, 360-366
  32. Lee JS, Lee JC, Lee CM, Jung ID, Jeong YI, Seong EY, Chung HY, Park YM (2007). Outer membrane protein A of Acinetobacter baumannii induces differentiation of CD4+ T cells toward a Th1 polarizing phenotype through the activation of dendritic cells. Biochem Pharmacol 74, 86-97
  33. Li ZT, Zhang RL, Bi XG, et al (2015). Outer membrane vesicles isolated from two clinical Acinetobacter baumannii strains exhibit different toxicity and proteome characteristics. Microb. Pathog. 81, 46-52
  34. Longo F, Vuotto C, Donelli G (2014). Biofilm formation in Acinetobacter baumannii. New Microbiologica 37, 119-127
  35. Luke NR, Sauberan, SL, Russo TA, et al (2010). Identifcation & characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis. Infect. Immun. 78, 2017-2023
  36. Mattsby-Baltzer I, Lindgren K, Lindholm B, Edebo L (1991). Endotoxin shedding by enterobacteria: free and cell-bound endotoxin differ in Limulus activity. Infect. Immun. 59, 689-695
  37. McConnell MJ, Actis L, Pachon J (2013). Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev 37, 130-155
  38. Mewo MES (2017). Pengaruh induksi glukosa terhadap pembentukan biofilm isolat klinis Acinetobacter baumannii dari urine kateter indwelling pasien non diabetes mellitus. Surabaya, Faculty of Medicine, Universitas Airlangga
  39. Mussi MA, Limansky AS, Viale AM (2005). Acquisition of resistance to carbapenems in multi-drug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of b-barrel outer membrane proteins. Antimicrob Agents Chemother 49, 1432-1440
  40. Neely AN, Maley MP, Warden GD (1999). Computer keyboards as reservoirs for Acinetobacter baumannii in a burn hospital. Clin Infect Dis 29, 1358-1360
  41. Neely AN (2000). A survey of gram-negative bacteria survival on hospital fabrics and plastics. J Burn Care Rehabil 21, 523-527
  42. NICE Guidelines. (2004. Type 1 diabetes: diagnose & manangement of type 1 diabetes in children, young people and adults. NICE Clinical Guideline 15. Available at http://www.nice.org.uk/guidance/CG15, http://www.nice.org.uk/guidance/CG66. Accessed July 18, 2018
  43. Roca I, Espinal P, Vila-Farres X, Vila J (2012). The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Front Microbiol 3, 148
  44. Rossi E, Longo F, Barbagallo M, Peano C, Consolandi C, Pietrelli A, Jaillon S, Garlanda C, Landini P (2016). Glucose aviability enhances lipopolysaccharide production and immunogenicity ini opportunistic pathogen Acinetobacter baumannii. Future Microbiology Ltd. DOI: 10.2217/FMB.15.153
  45. Safari M, Nejad ASM, Bahador A, Jafari R, AlikhanI MY (2015). Prevalence of ESBL and MBL encoding genes in Acinetobacter baumannii strains isolated from patients of intensive care units (ICU). Saudi journal of biological sciences 22, 424-9
  46. Seifert H, Strate A, Pulverer G (1995). Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine 74, 340-349
  47. Shin JB, Lee HW, Kim SM, Kim J (2009). Proteomic analysis of Acinetobacter baumannii in biofilm and planktonic growth mode. J. Microbiol 47, 728-735
  48. Sukanya S, Lakshmi V, Padmaja K (2014). Prevalence of multidrug resistant Acinetobacter baumannii in clinical samples in a tertiary care hospital. Int J Infect Control V11, i3
  49. Talbot GH, Bradley J, Edwards JE, Jr, Gilbert D, Scheld M, Bartlett JG (2006). Antimicrobial Availability Task Force of the Infectious Diseases Society of America: Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42, 657-668
  50. Towner KJ, Bergogne-Bérézin E, Fewson CA (1991). Acinetobacter: Portrait of a genus. The biology of Acinetobacter: taxonomy, clinical importance, molecular biology, physiology, industrial relevance. FEMS Symposium 57, 1-24
  51. Towner KJ (2009). Acinetobacter: an old friend, but a new enemy. J Hosp Infect 73, 355-363
  52. Trautner BW, Darouiche RO (2004). Role of biofilm in catheter associated urinary tract infections. Am. J. Infect. Control 32, 177-83
  53. Vijayakumar S, Rajenderan S, Laishram S, Anandan S, Balaji V, Biswas I (2016). Biofilm formation and motility depend on the nature of the Acinetobacter baumannii Clinical Isolates. Front Public Health 4, 105
  54. Vila J, Marcos A, Marco F, Abdalla S, Bergara Y, Reig R, Gomez-Lus R, Jimenez de Anta T (1993). In vitro antimicrobial production of ß-lactamases, aminoglycosidemodifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 37, 138-141
  55. Villegas MV, Hartstein AI (2003). Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 24, 284-295
  56. Wisplinghoff H, Perbix W, Seifert H (1999). Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 28, 59-66
  57. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004). Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39, 309-317
  58. Yanong I, Ramli S, Widodo ADW, Wasito EB (2017). Pola kepekaan antibiotika Acinetobacter baumannii dari spesimen sputum di RSUD dr. Soetomo Surabaya Periode Januari 2017-Juni 2017. Pertemuan Ilmiah Tahunan Persatuan Ahli Mikrobiologi Klinik Padang Tahun 2017
  59. Zarrilli R (2016). Acinetobacter baumannii virulence determinants involved in biofilm growth and adherence to host epithelial cells. Virulence 7, 367-368. DOI: 10.1080/21505594.2016.1150405

Most read articles by the same author(s)